Print this page    •   Back to Web version of article

U.S. News
Johnson & Johnson Unit Submits HIV Drug Candidate to FDA for Approval

July 20, 2007

On Wednesday, Johnson & Johnson's Tibotec Pharmaceuticals Ltd. division said it had filed a new application for Food and Drug Administration approval of TMC125 (etravirine), its new HIV drug candidate. FDA's decision to fast-track TMC125 means the company can submit data as it becomes available, rather than all at once. The treatment for people infected with HIV-1 is meant to be administered with other antiretrovirals.

Back to other news for July 2007

Search the Newsroom archive

Excerpted from:
Associated Press
07.18.2007



This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/treat/art42406.html

General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.